ChemoMetec

ChemoMetec A/S has announced a notification regarding transactions involving its shares, conducted by individuals with managerial responsibilities or their associates, in compliance with EU Regulation no. 596/2014. The transactions pertain to Martin Glensbjerg, Vice Chair of ChemoMetec's Board of Directors, and details can be found in the attached PDF document. ChemoMetec, established in 1997 and listed on Nasdaq OMX Copenhagen, specializes in the development and marketing of cell counting instruments for various industries. For more information, contact Kim Nicolajsen, CFO, at (+45) 48 13 10 20 or visit www.chemometec.com.

ChemoMetec A/S announced that it has received a notification regarding transactions involving its shares by individuals in managerial roles or closely associated with them, as required by EU Regulation no. 596/2014. The transactions involving CEO Martin Helbo Behrens are detailed in an attached PDF document. ChemoMetec, established in 1997 and listed on Nasdaq OMX Copenhagen, develops and markets cell counting instruments and other measurement tools for various industries globally. For more details, contact Kim Nicolajsen, CFO, or visit the company’s website.

In the first quarter of the 2024/25 financial year, ChemoMetec reported a 27% increase in revenue to DKK 115.6 million, driven by higher sales of instruments, consumables, and services across regions, particularly in the USA/Canada. Operating profit (EBITDA) rose by 50% to DKK 62.1 million, with an EBITDA margin of 54%. Notable growth was seen in the sales of instruments, especially the NC-200, NC-202, XM30, and XM40 models. ChemoMetec's largest business area, LCB, saw a 29% revenue increase. On 22 October 2024, ChemoMetec acquired Ovizio Imaging Systems SA, a company specializing in cell counters for bioprocessing. The acquisition is not expected to affect the company's profit guidance, which was recently upgraded for the full year 2024/25.

ChemoMetec has completed the acquisition of Ovizio Imaging Systems SA, a Belgian company, for EUR 2,830,000. Ovizio specializes in cell counters based on holographic microscopy, used mainly in bioprocessing and cell and gene therapy. The company reported EUR 1.4 million in revenue in 2023. ChemoMetec, founded in 1997 and listed on Nasdaq OMX Copenhagen, develops and markets instruments for cell counting and other measurements, serving the pharmaceutical, biotech, and agricultural industries. For additional information, contact Martin Helbo Behrens, CEO, or Kim Nicolajsen, CFO.

ChemoMetec has submitted a binding offer to acquire 100% of Ovizio Imaging Systems SA for EUR 2,830,000. Shareholders owning more than two-thirds of Ovizio have accepted the offer, and ChemoMetec is seeking acceptance from the remaining shareholders, who are legally obliged to do so. The acquisition is expected to close within a week. After completion, ChemoMetec will begin developing Ovizio but does not anticipate any impact on its recent financial guidance. Ovizio specializes in holographic microscopy-based cell counters used in bioprocessing and cell and gene therapy, with significant revenue from consumables and service contracts. ChemoMetec, founded in 1997 and listed on Nasdaq OMX Copenhagen, provides instruments for cell counting and other measurements to various industries.

ChemoMetec has upgraded its revenue and operating profit guidance for the 2024/25 financial year following a strong first quarter with better-than-expected sales and order intake. The company now anticipates revenue in the range of DKK 445-460 million, up from the previous guidance of DKK 435-450 million, and EBITDA in the range of DKK 222-230 million, up from DKK 216-223 million. ChemoMetec's interim report for Q1 2024/25 will be released on November 7, 2024. ChemoMetec, founded in 1997 and listed on Nasdaq OMX Copenhagen, develops and markets instruments for cell counting and other measurements, serving industries such as pharmaceutical, biotech, and agriculture worldwide.

ChemoMetec has expressed interest in acquiring the Belgian company Ovizio Imaging Systems SA and has made an indicative purchase offer. The due diligence process and negotiations for the final share purchase agreement are still underway. If these are completed successfully, ChemoMetec expects to finalize the acquisition in the coming weeks. Ovizio specializes in a cell counter using holographic microscopy, mainly used in bioprocessing and cell and gene therapy. In 2023, Ovizio reported a revenue of EUR 1.4 million. ChemoMetec, established in 1997 and listed on Nasdaq OMX Copenhagen, develops and markets instruments for cell counting and other measurements to industries worldwide.

The Annual General Meeting of ChemoMetec A/S took place on 10 October 2024 at Nordsjællands KonferenceCenter. During the meeting, the Board of Directors presented their report on the past year's activities, the annual report for 2023/24 was approved, and the Board and Executive Board were discharged. A dividend of DKK 4 per share was approved. Niels Thestrup, Martin Glensbjerg, Kristine Færch, Betina Hagerup, and Peter Reich were re-elected to the Board of Directors, and Deloitte was re-elected as auditor. The meeting also approved the remuneration policy and report, and authorized the Board to acquire treasury shares. After the meeting, Niels Thestrup and Martin Glensbjerg were re-elected as chairman and deputy chairman, respectively. ChemoMetec A/S specializes in developing instruments for cell counting and other measurements for various industries and is listed on Nasdaq OMX Copenhagen.

ChemoMetec has made an indicative offer to acquire Ovizio Imaging Systems, a Belgian company specializing in cell counting technology using holographic microscopy. The offer has been accepted by Ovizio's owners, and ChemoMetec has three weeks to conduct due diligence. If the results are favorable, ChemoMetec is likely to proceed with the acquisition. Ovizio's cell counter is used in bioprocessing and cell and gene therapy, and its product connects directly to bioreactors for continuous cell analysis. In 2023, Ovizio reported revenue of EUR 1.4 million, mainly from consumables and service contracts. ChemoMetec's management believes the acquisition would complement their technologies in the market for automated and integrated cell counting. The impact on ChemoMetec's financial guidance for 2024/25 is currently uncertain. For more information, contact CEO Martin Helbo Behrens or CFO Kim Nicolajsen. ChemoMetec, founded in 1997 and listed on Nasdaq OMX Copenhagen, develops and markets instruments for cell counting and other measurements to various industries, including pharmaceuticals and biotech.

Announcement No. 275, dated 18 September 2024, informs about the Annual General Meeting of ChemoMetec A/S, scheduled for Thursday, 10 October 2024, at 5:30 p.m. The meeting will take place at Nordsjællands KonferenceCenter, Gydevang 39-41, 3450 Allerød. For additional information, Kim Nicolajsen, CFO, can be contacted at (+45) 48 13 10 20. ChemoMetec A/S, established in 1997 and listed on Nasdaq OMX Copenhagen, develops, manufactures, and markets instruments for cell counting and other measurements for the pharmaceutical, biotech, and agricultural industries globally. More details can be found at www.chemometec.com. An attachment with the AGM agenda is included.